Comparative Pharmacology
Head-to-head clinical analysis: CHOLESTYRAMINE versus CHOLESTYRAMINE LIGHT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLESTYRAMINE versus CHOLESTYRAMINE LIGHT.
CHOLESTYRAMINE vs CHOLESTYRAMINE LIGHT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cholestyramine is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and decreased serum low-density lipoprotein (LDL) cholesterol levels.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby preventing enterohepatic recirculation of bile acids and promoting hepatic conversion of cholesterol to bile acids, reducing serum LDL-cholesterol.
4 g orally once or twice daily, titrated up to 24 g/day divided into 2-6 doses; usual maintenance dose 8-16 g/day
4 g orally once or twice daily, increased gradually to 4 g 1-6 times daily; maintenance 4-24 g/day in divided doses.
None Documented
None Documented
Not applicable; cholestyramine is not absorbed and does not have a systemic half-life. Its clinical effect is related to gastrointestinal transit time.
Not applicable; cholestyramine is not absorbed systemically and has no plasma half-life; clinical effect duration reflects gastrointestinal transit time.
Cholestyramine is not absorbed systemically; it remains in the gastrointestinal tract and is excreted unchanged in feces. No renal or biliary elimination occurs.
Primarily fecal as bile acid complex; <0.05% renal excretion of unchanged drug; negligible systemic absorption.
Category C
Category C
Bile Acid Sequestrant
Bile Acid Sequestrant